Sartorius shares strongly sought after good third quarter: pharmaceutical supplier is becoming a little more optimistic

In addition, the target for the operating margin was specified. Revenue is expected to increase by around 7 percent at group level in the current year, as the group, which was recently relegated from the DAX to the MDAX, announced on Thursday in Göttingen. The new target is at the upper end of the range previously envisaged. Sartorius had previously expected an increase of around 6 percent with a forecast corridor of around plus and minus two percentage points. Sartorius now expects the margin, measured by earnings before interest, taxes, depreciation and amortization (Ebitda) adjusted for special effects, to be just over 29.5 percent for the current year. The company had previously targeted a figure of around 29 to 30 percent.

Sartorius shares rise – numbers ‘good enough for price recovery’

Thanks to encouraging business figures, Sartorius’ preferred shares broke out of their sideways range of the past few days with a price jump on Thursday. The laboratory and pharmaceutical supplier’s shares had now risen by a good 13 percent to 240.50 euros via XETRA, reaching their highest level since March.

Most recently there was an increase of 9.94 percent at 233.40 euros. This meant that the Sartorius stocks were ahead in the moderately rising MDAX of medium-sized stocks.

The recovery continues at Sartorius. After a good performance in the third quarter, the group slightly increased its sales forecast for the current year. The company’s figures are “good enough for a price recovery,” said one trader. Analyst Richard Vosser from the US bank JPMorgan described the figures as strong overall. The adjusted operating result was slightly better than the market expected.

The expert James Vane-Tempest from the analysis house Jefferies spoke of solid results. The fact that the Bioprocess Solutions division is now expected to reach the upper end of the previously defined forecast range of around nine percent in terms of growth from its own resources is likely to have been well received by the market. This is particularly encouraging given the persistently weak environment for medical equipment. In addition, the ratio of incoming orders to sales is “well above 1”. This is generally seen as a positive sign for demand.

With the price jump, the technical chart picture has also brightened significantly. Sartorius jumped above the widely watched 200-day moving average line, which is considered an indicator of the long-term trend.

GÖTTINGEN/FRANKFURT (dpa-AFX)

Selected leverage products on Sartorius vz.

With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Sartorius vz.

The leverage must be between 2 and 20

Advertising